Drug intelligence / Profile preview

RPH-001

Development stage: Phase 3
Lead developer: AlphaMab Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RPH-001 is a biosimilar of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By binding to VEGF-A, it inhibits angiogenesis—the formation of new blood vessels—thereby restricting tumor growth and maintenance. RPH-001 is being developed for the treatment of various cancers including non-small cell lung cancer, recurrent or metastatic colon cancer, breast cancer, ovarian cancer, renal cell carcinoma, and glioblastoma. The drug is administered intravenously. It is being developed by Jiangsu Alphamab Biopharmaceuticals and R-Pharm[1][2][3].

Brand names: AvziviPOBEVCY
Other names: bevacizumab biosimilarRPH 001RPH001RPH-001

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on RPH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPH-001.

Explore the full profile